UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

A class action lawsuit was filed against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility before resubmitting a New Drug Application to the FDA. The company's stock dropped 39.1% on June 30, 2026, when the FDA issued a Complete Response Letter citing the same manufacturing deficiencies previously identified. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible to participate in the lawsuit.